Dr. Reddy's acquires Louisiana BASF facility

CHARLOTTE, N.C. Dr. Reddy’s Laboratories has completed its acquisition of the BASF pharmaceutical contract manufacturing business and its facility in Shreveport, Louisiana.

Under the terms of the deal, Dr. Reddy acquires the company’s relevant business, customer contracts, related abbreviated and new drug applications, and trademarks, as well as the manufacturing facility and assets in Shreveport. The relevant business includes the contract manufacturing of generic prescription and over-the-counter products for branded and generic companies in the U.S. The facility is set-up to manufacture solid, semi-solid and liquid dosage forms.

Mark Hartman, president of North America Generics at Dr. Reddy’s, said, “We are excited about this acquisition, as this facility provides us with a profitable revenue base built on strong customer relationships with branded and generic companies. It also provides us with an additional platform to further expand our prescription generic and OTC capabilities, and our general product portfolio, as well as the ability to supply generic products to US government agencies.”